Loading clinical trials...
Loading clinical trials...
A MULTICENTER, GLOBAL, RANDOMIZED, DOUBLE-BLIND STUDY OF AXITINIB PLUS BEST SUPPORTIVE CARE VERSUS PLACEBO PLUS BEST SUPPORTIVE CARE IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA FOLLOWING FAILURE OF ONE PRIOR ANTIANGIOGENIC THERAPY
Conditions
Interventions
Axitinib (AG-013736)
Best Supportive Care
+2 more
Locations
77
United States
Alta Bates Summit Comprehensive Cancer Center
Berkeley, California, United States
UCSD Medical Center- La Jolla
La Jolla, California, United States
Moores UCSD Cancer Center
La Jolla, California, United States
University of California Irvine Medical Center
Orange, California, United States
UCSD Medical Center- Hillcrest
San Diego, California, United States
Florida Hospital Transplant Center, Liver Unit
Orlando, Florida, United States
Start Date
December 6, 2010
Primary Completion Date
March 3, 2014
Completion Date
December 20, 2016
Last Updated
January 9, 2019
NCT07175441
NCT05969860
NCT06427941
NCT05842174
NCT07164313
NCT07118202
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions